A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study).

Abstract

BACKGROUND:

Liraglutide is an effective treatment for the management of type 2 diabetes mellitus (T2DM). In addition to glycemic control and potential cardioprotective effects, recent studies suggest a possible role for liraglutide in the inhibition of platelet reactivity, further attenuating atherothrombotic risk in patients with T2DM. We evaluated the in-vivo antiplatelet effect of liraglutide in T2DM patients without macrovascular disease or concurrent anti-platelet therapy.

METHODS:

A double-blind, placebo-controlled pilot study of 16 T2DM patients, 51-69 y/o, (mean age 60.4 y/o, 63.0% male) randomised to receive liraglutide (1.8 mg/day) or placebo (saline) for 6 months was conducted. Platelet aggregation studies at baseline and after initiation of the study intervention: days 1, 7, and 14 and months 1, 3 and 6 were performed.

RESULTS:

Liraglutide (n = 7) and placebo (n = 9) treated patients demonstrated normal platelet aggregation responses although transient and significant attenuation in maximum slope of platelet aggregation in response to collagen (p ≤ 0.05), arachidonic acid (p ≤ 0.05) and ADP (p ≤ 0.02) was observed in liraglutide compared to placebo treated patients in the first week.

CONCLUSIONS:

In this pilot study of patients with T2DM liraglutide treatment was associated with a significant, early and transient decrease in maximum slope of platelet aggregation. The clinical significance of this effect is currently unknown and may warrant further investigation.

CLINICAL TRIAL REGISTRATION NUMBER:

UTN 1111-1181-9567.

• Authors: Jayasree Loganathan, Adam C Cohen, Georgia M Kaloupis, Carolyn Harris, Andriana Chronopoulos, Vanessa James, Justin Hamilton, Sarah Green, Andrew Wallis, Susan Morgan, Raymond Dauer, Christopher Gilfillan, Anthony E Dear
• Journal: Journal of diabetes and its complications (J Diabetes Complications) Vol. 36 Issue 5 Pg. 108188 (05 2022) ISSN: 1873-460X [Electronic] United States
• PMID: 35382966 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• Hypoglycemic Agents
• Liraglutide

Topics

• Diabetes Mellitus, Type 2 (chemically induced, complications, drug therapy)
• Double-Blind Method
• Female
• Humans
• Hypoglycemic Agents (pharmacology, therapeutic use)
• Liraglutide (pharmacology, therapeutic use)
• Male
• Middle Aged
• Pilot Projects